ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.78 USD
-3.82%
Market Closed
Updated:
Apr 25, 2024
ADC Therapeutics SA
Total Equity
Last
Value
3-Years CAGR
5-Years CAGR
|
ADC Therapeutics SA
Total Equity Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Total Equity
-$148.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Total Equity
CHf160.6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Equity
$1.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Equity
-CHf10m
|
CAGR 3-Years
54%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Equity
-CHf661m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Equity
CHf56.7m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Total Equity?
Total Equity
-148.2m
USD
-148.2m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Total Equity amounts to -148.2m USD.
You don't have any saved screeners yet
